Lexicon Pharma (LXRX) Tops Q4 EPS by 3c
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $2.16 +0.47%
Revenue Growth %: -86.1%
Financial Fact:
Loss from operations: -34.93M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Revenue Growth %: -86.1%
Financial Fact:
Loss from operations: -34.93M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q4 EPS of ($0.04), $0.03 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $5.5 million versus the consensus estimate of $3.92 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Lockheed Martin wins $8.4B missile contract modification
- KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
